Robert Weiss
About
Robert Weiss is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism.
According to data from OpenAlex, Robert Weiss has authored 109 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Cardiology and Cardiovascular Medicine, 31 papers in Surgery and 15 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Robert Weiss's work include Blood Pressure and Hypertension Studies (24 papers), Lipoproteins and Cardiovascular Health (20 papers) and Pharmaceutical Economics and Policy (10 papers). Robert Weiss is often cited by papers focused on Blood Pressure and Hypertension Studies (24 papers), Lipoproteins and Cardiovascular Health (20 papers) and Pharmaceutical Economics and Policy (10 papers). Robert Weiss collaborates with scholars based in United States, Australia and Canada. Robert Weiss's co-authors include Daniel Gaudet, M H Weinberger, Barbara Roniker, Scott Krause, Henry R. Black, Evan A. Stein, Jean Bergeron, Robert Dufour, Robert Pordy and Richard Wu and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Robert Weiss
102 papers receiving 5.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Weiss United States | 34 | 2.3k | 2.1k | 1.4k | 777 | 483 | 109 | 5.4k | ||
| Jerome D. Cohen United States | 36 | 3.0k 1.3× | 1.7k 0.8× | 1.4k 1.0× | 564 0.7× | 455 0.9× | 105 | 6.1k | ||
| Guðmundur Þorgeirsson Iceland | 32 | 2.1k 0.9× | 2.1k 1.0× | 1.7k 1.3× | 474 0.6× | 835 1.7× | 85 | 5.7k | ||
| Stephen P. Glasser United States | 43 | 3.3k 1.4× | 1.3k 0.6× | 800 0.6× | 341 0.4× | 490 1.0× | 210 | 6.0k | ||
| Deborah R. Shapiro United States | 27 | 2.2k 0.9× | 5.0k 2.4× | 2.3k 1.7× | 1.6k 2.0× | 519 1.1× | 81 | 9.7k | ||
| Andrew M. Tershakovec United States | 24 | 1.3k 0.5× | 3.6k 1.7× | 1.5k 1.1× | 1.3k 1.7× | 275 0.6× | 55 | 5.1k | ||
| Jeffrey Kluger United States | 40 | 3.2k 1.4× | 1.2k 0.6× | 376 0.3× | 294 0.4× | 508 1.1× | 285 | 5.9k | ||
| Stephen L. Kopecky United States | 40 | 4.0k 1.7× | 1.6k 0.8× | 485 0.4× | 477 0.6× | 917 1.9× | 149 | 7.8k | ||
| J. Tuomilehto Finland | 27 | 870 0.4× | 1.7k 0.8× | 1.9k 1.4× | 287 0.4× | 479 1.0× | 54 | 4.8k | ||
| Y. Antero Kesäniemi Finland | 31 | 1.9k 0.8× | 1.1k 0.5× | 621 0.5× | 259 0.3× | 326 0.7× | 58 | 4.5k | ||
| Kåre Berg Norway | 37 | 1.2k 0.5× | 3.5k 1.7× | 1.8k 1.3× | 479 0.6× | 808 1.7× | 147 | 6.3k |
Countries citing papers authored by Robert Weiss
Since
Specialization
Citations
This map shows the geographic impact of Robert Weiss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Weiss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Weiss more than expected).
Fields of papers citing papers by Robert Weiss
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert Weiss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Weiss. The network helps show where Robert Weiss may publish in the future.
Co-authorship network of co-authors of Robert Weiss
This figure shows the co-authorship network connecting the top 25 collaborators of Robert Weiss. A scholar is included among the top collaborators of Robert Weiss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Weiss. Robert Weiss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wang, Wenshen, Zheng Han, Олеся Гололобова, et al.. (2025). Magnetically Labelled iPSC‐Derived Extracellular Vesicles Enable MRI/MPI‐Guided Regenerative Therapy for Myocardial Infarction. Journal of Extracellular Vesicles. 14(10). e70178–e70178.
2.
Stein, Evan A., Ransi Somaratne, Fernando Civeira, et al.. (2013). Abstract 12621: Efficacy and Tolerability of Long-Term Treatment With AMG 145 in Patients With Statin Intolerance. Circulation.
3.
Ananthasubramaniam, Karthikeyan, et al.. (2011). A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND TOLERANCE OF REGADENOSON IN PATIENTS WITH RENAL IMPAIRMENT. Journal of the American College of Cardiology. 57(14). E650–E650.
4.
Weiss, Robert, et al.. (2011). Efficacy and Tolerability of Nebivolol in Stage I–II Hypertension: A Pooled Analysis of Data From Three Randomized, Placebo-Controlled Monotherapy Trials. Clinical Therapeutics. 33(9). 1150–1161.
5.
Townsend, Ray, Neville Bittar, Jeffrey B. Rosen, et al.. (2008). Abstract 4431: Differential Blood Pressure Effect of Naproxcinod Compared with Naproxen on Ambulatory Blood Pressure in Hypertensive Subjects. Circulation. 118.
6.
Moore, Steven A., et al.. (2008). Cardiac damage after lesions of the nucleus tractus solitarii. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 296(2). R272–R279.
7.
Black, Henry R., George L. Bakris, Michael A. Weber, et al.. (2007). Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Study. Journal of Clinical Hypertension. 9(10). 760–769.
8.
Ballantyne, Christie M., Marcelo Chiara Bertolami, Evan A. Stein, et al.. (2006). Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. American Heart Journal. 151(5). 975.e1–975.e9.
9.
Mor‐Avi, Victor, Lawrence Jacobs, Robert Weiss, et al.. (2006). Color Encoding of Endocardial Motion Improves the Interpretation of Contrast-enhanced Echocardiographic Stress Tests by Less-experienced Readers. Journal of the American Society of Echocardiography. 19(1). 48–54.
10.
Vicari, Ralph, Bernard Chaitman, Deborah Keefe, et al.. (2005). Efficacy and Safety of Fasudil in Patients With Stable Angina. Journal of the American College of Cardiology. 46(10). 1803–1811.
11.
Weiss, Robert, et al.. (2003). The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clinical Therapeutics. 25(5). 1490–1497.
12.
Pepine, Carl J., Rhonda M. Cooper‐DeHoff, Robert Weiss, et al.. (2003). Comparison of Effects of Nisoldipine-Extended Release and Amlodipine in Patients With Systemic Hypertension and Chronic Stable Angina Pectoris. The American Journal of Cardiology. 91(3). 274–279.
13.
Cushman, William C., Charles E. Ford, Jeffrey A. Cutler, et al.. (2002). Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension. 4(6). 393–404.
14.
Weinberger, M H, Barbara Roniker, Scott Krause, & Robert Weiss. (2002). Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. American Journal of Hypertension. 15(8). 709–716.
15.
Weiss, Robert. (1998). Fluvastatin Titrate-to-Goal Clinical Practice Study. American Journal of Therapeutics. 5(5). 281–286.
16.
Gradman, Alan H., et al.. (1997). Combined Enalapril and Felodipine Extended Release (ER) for Systemic Hypertension. The American Journal of Cardiology. 79(4). 431–435.
17.
Glasser, Stephen P., Steven R. Ripa, Robert Weiss, et al.. (1995). Antianginal and Antiischemic Efficacy of Monotherapy Extended‐Release Nisoldipine (Coat Core) in Chronic Stable Angina. The Journal of Clinical Pharmacology. 35(8). 780–784.
18.
Chahine, Robert A., Robert L. Feldman, Thomas D. Giles, et al.. (1993). Randomized placebo-controlled trial of amlodipine in vasospastic angina. Journal of the American College of Cardiology. 21(6). 1365–1370.
19.
Packer, Milton, Pascal Nicod, Alan G. Wasserman, et al.. (1991). Randomized, multicenter, double-blind, placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure. Journal of the American College of Cardiology. 17(2). A274–A274.
20.
Weiss, Robert & Charles B. Smith. (1983). Altered platelet alpha2-adrenoceptors in patients with angina pectoris. Journal of the American College of Cardiology. 2(4). 631–637.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jerome D. Cohen Breakdown of academic impact, for papers by Guðmundur Þorgeirsson Breakdown of academic impact, for papers by Stephen P. Glasser Breakdown of academic impact, for papers by Deborah R. Shapiro Breakdown of academic impact, for papers by Andrew M. Tershakovec Breakdown of academic impact, for papers by Jeffrey Kluger Breakdown of academic impact, for papers by Stephen L. Kopecky Breakdown of academic impact, for papers by J. Tuomilehto Breakdown of academic impact, for papers by Y. Antero Kesäniemi Breakdown of academic impact, for papers by Kåre Berg